fbpx

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Myeloma Chemotherapy- Hey FDA! 5-7 years?!

Share Button

“Our results suggest that the FDA may be approving many (myeloma chemotherapy drugs) costly, toxic drugs that do not improve overall survival,”

If you have been diagnosed with multiple myeloma (MM), the good news is that there is a long and growing list of myeloma chemotherapy regimens. Your oncologist probably will instruct you to undergo one or more chemotherapies such as Velcade, Revlimid, Dexamethasone, etc.

And then you may be told you should have an autologous stem cell transplant (ASCT)– high-dose chemotherapy. Both are FDA approved “standard-of-care” regimens. An autologous stem-cell transplant does NOT increase overall survival when compared to novel chemotherapies. But it does, on average, incure a higher rate of short, long-term and late stage side-effects and it costs you and your insurance company much more than a course of novel chemotherapy drugs.

If you are like me, you assumed that this toxic, collateral damage-inducing therapy would help you live longer. I assumed incorrectly… According to the article linked and excerpted below, for years now, the FDA has approved myeloma chemotherapy drugs that increase the average remission but not the average length of life or overall survival.

So why does the American Cancer Society say that the average life expectancy of newly diagnosed MM patients is 43-83 months?

Revised International Staging System- Median Survival

Stage I      Has not been reached

Stage II     83 months

Stage III   43 months

While it is true that there are long MM remissions (longer than the ACS averages…) these days. However, even with many novel MM chemotherapies approved by the FDA since I was diagnosed in ’94, the average five year survival rate for MM is 49%. In other words, the FDA is approving chemotherapy regimens that increase the survival of a small percentage of MMers but not the majority of MMers.

The study linked and excerpted below talks about how the FDA frequently approves chemotherapies that don’t increase overall survival for cancer patients. There are more myeloma chemotherapy drugs for each patient to try, but MM patients live about the same amount of time as they have for years now.

The National Cancer Institute (NCI) lists more than 17 chemotherapies  that have been approved for treatment of MM. Yet there is no mention of the dozens of evidence-based, non-toxic therapies that can help MMers live longer. Or the many therapies that integrate with conventional chemotherapy to enhance the efficacy of the chemo while reducing its toxicity.

The fact is that multiple myeloma is a complicated, aggressive cancer. As a long-term myeloma survivor myself, I believe newly diagnosed patients must think outside the conventional MM box. MM patients must use every evidence-based therapy at their disposal.

I live a non-conventional, non-toxic MM lifestyle. I have been in complete remission since 1999. Anti-MM nutrition, supplementation, lifestyle, bone health and even mind-body therapies.

Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.

To learn more about cultivating deeper and longer remissions, click here.

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Approved But Not Proven: What’s Up With FDA, Cancer Drugs?

“In approving new cancer drugs, the US Food and Drug Administration (FDA) is now heavily relying on surrogate markers of effectiveness, such as tumor shrinkage, instead of proof that an agent improves survival, according to a new analysis.

The investigators conclude that this might be having a deleterious effect on patients, public health, and healthcare costs.

“Our results suggest that the FDA may be approving many costly, toxic drugs that do not improve overall survival,” write Chul Kim, MD, MPH, from the National Cancer Institute (NCI), and Vinay Prasad, MD, MPH, from the Knight Cancer Center at the Oregon Health and Sciences University in Portland.

Their analysis showed that 36 of 54 (67%) cancer drug approvals from 2008 to 2012 were made on the basis of surrogate markers — either tumor response rate or progression-free survival, in about equal frequency.

The team’s research letter was published online October 19 in JAMA Internal Medicine.

Only two things matter in patient care: living longer and living better.

“Doctors must remember that only two things matter in patient care: living longer and living better. Surrogate end points address neither issue head on, and always require follow-up,” Dr. Prasad told Medscape Medical News

“Cancer drugs are good at killing cancer cells,” Dr. Zuckerman told Medscape Medical News. Thus, tumors respond to the toxic agents and die or shrink, which is typically captured by radiographic imaging and is reported as an overall rate in clinical trials. But the problem is that they also kill healthy cells, and overall survival might not improve.

“It’s important to know if the patient will live longer,” she said.

In their study, half the drugs (18 of 36) approved on the basis of surrogate markers were eventually found to not improve survival, Drs Kim and Prasad report

 

 

Leave a Comment:

4 comments
Top Multiple Myeloma Hospitals, Multiple Myeloma Specialists - PeopleBeatingCancer says a couple of years ago

[…] Myeloma Chemotherapy- Hey FDA! 5-7 years?! […]

Reply
Multiple Myeloma Chemotherapy- Overall Survival vs. Progression-free survival - PeopleBeatingCancer says a couple of years ago

[…] Myeloma Chemotherapy- Hey FDA! 5-7 years?! […]

Reply
Role of Autologous Stem Cell Transplant for You-Multiple Myeloma - PeopleBeatingCancer says 3 years ago

[…] Hey FDA! The Average Survival of Myeloma Patients is 5-7 years!?! When is back pain not back pain? Autologous Stem Cell Transplant Show NO OVERALL SURVIVAL for Myeloma Cannabidiol (CBD) as Multiple Myeloma therapy- […]

Reply
Multiple Myeloma- Diagnosis and Staging - PeopleBeatingCancer says 4 years ago

[…] Hey FDA! The Average Survival of Myeloma Patients is 3-5 years!?! […]

Reply
Add Your Reply